Virometix
Chemicals & Related Products · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Wagisstrasse 14, Schlieren, Zurich, 8952...Phone Number
+41 434338660Website
www.virometix.comRevenue
$10.7 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Virometix
Virometix AG is a clinical stage biotech company focused on developing a new class of synthetic vaccines aimed at combating infectious diseases. Utilizing a proprietary modular nanoparticle technology platform, their vaccines are designed to elicit a precise and sustained immune response while being safe, cost-effective, and scalable. The company is currently advancing a portfolio of vaccine candidates, including a first-in-class serotype-independent vaccine for Streptococcus pneumoniae and epitope-specific vaccines for Respiratory Syncytial Virus. Virometix AG targets healthcare providers and organizations seeking innovative solutions to address high unmet medical needs in infectious disease prevention.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Virometix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Virometix launches new products
Virometix, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Virometix has new funding data
Check if Virometix has recently received funding, and reach out quickly before it becomes old news!
Click to see if Virometix had a recent Job posting/layoffs
Earning: See what the market has to say on Virometix recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Virometix is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Virometix
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Virometix is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Virometix is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Virometix.
Virometix financials insights
Gather financial insights about Virometix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$5.1M
2020
Series B
$7.9M
2025
Unspecified
$15M
Virometix Tech Stack
A closer look at the technologies used by Virometix
Most Recent Scoops
Funding
Funding
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Funding
Virometix News & Media
Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has neaVirometix Announces Publication of Key Non-Clinical Proof-of-Concept Data in Two High Quality Peer-Reviewed Journals
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases and cancer conditions, today announces publication of key non-clinical proof-of-concept data on its lead vaccine candidate V-306 in two high quality peer-reviewed journals. The data confirm the potential of V-306 for prophylaxis against Respiratory Syncytial Virus (RSV) infectiVirometix Broadens Senior Leadership Team with Three Key Appointments
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, today announced the expansion of its leadership team with the appointment of a Chief Scientific Officer and two additional Board members. Virometix filled a vacancy in its management team with the appointment of Dr. Lilli Stergiou to the position of Chief ScientifVirometix Announces Completion of Initial Vaccination of the First Dose Cohort in Phase 1 Study with V-306
SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced today the completion of initial vaccination of the first dose cohort in the Phase 1 healthy volunteer study of V-306, its candidate vaccine for prophylaxis of RSV (Respiratory Syncytial Virus) infection in neonates. All 20 subjects received the first dos
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Virometix
Sign Up For FreeTo access detailed company insights
Virometix AG is a clinical stage biotech company focused on developing a new class of synthetic vaccines aimed at combating infectious diseases. Utilizing a proprietary modular nanoparticle technology platform, their vaccines are designed to elicit a precise and sustained immune response while being safe, cost-effective, and scalable. The company i... Read More
